Ownership history in RTW INVESTMENTS, LP Β· 21 quarters on record
This page tracks every 13F SEC filing in which RTW INVESTMENTS, LP reported a position in Tarsus Pharmaceuticals Inc. (TARS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π RTW INVESTMENTS, LP outperformed the S&P 500 by +72.1% annually on this TARS position. Timing score: 50% (6/12 decisions correct). Average cost basis: $36.05. Maximum drawdown during holding period: β69.6%.
π₯ Exceptional β beat the S&P 500 by 72.1% per year on this position.
11 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
6 of 12 add/trim decisions correct
Best entry: $14.66 (2022 Q4) Β· Worst: $81.88 (2025 Q4)
πͺ Held through 2 major drawdowns (>20%).
10 adds Β· 3 trims. Bought during 4 of 11 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 2.74% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size